about
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.Comparative Effects of Metal-Catalyzed Oxidizing Systems on Carbonylation and Integrity of Therapeutic Proteins.Methodological approaches and insights on protein aggregation in biological systems.Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbsCell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon betaImproving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.Phosphatidylserine is not just a cleanup crew but also a well-meaning teacher.
P2860
Q36739647-B995E3FB-7582-436D-A41A-360F00CB4832Q38616024-0070DBBE-995D-438B-B4F3-467C6EC3A5F6Q38790062-8916AEBB-E45A-4D76-BE85-D40D8137AE83Q38887796-54035C52-8949-458D-8BFA-525620FA1176Q41620233-E2903E1D-8D0B-443B-9458-38C1E8768E36Q51602149-BD9B7B56-CDE4-4594-AFB3-C63015DE4D07Q52591717-78285FE9-E97B-4830-8A2D-74D595DA71EB
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
New FDA draft guidance on immunogenicity.
@en
New FDA draft guidance on immunogenicity.
@nl
type
label
New FDA draft guidance on immunogenicity.
@en
New FDA draft guidance on immunogenicity.
@nl
prefLabel
New FDA draft guidance on immunogenicity.
@en
New FDA draft guidance on immunogenicity.
@nl
P2093
P2860
P1433
P1476
New FDA draft guidance on immunogenicity.
@en
P2093
Amy Rosenberg
Ashwin Parenky
Heather Myler
Karoline Bechtold-Peters
Lakshmi Amaravadi
Susan Kirshner
Valerie Quarmby
P2860
P2888
P304
P356
10.1208/S12248-014-9587-6
P407
P577
2014-03-29T00:00:00Z
P6179
1045665857